Recent Updates
Recently added Catalysts

ABI-009

Phase 1

Solid Tumors | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Oct 18, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment27
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00635284ABI-009 Trial in Patients With Advanced Non-hematologic MalignanciesPHASE1 COMPLETED 27 — — Dec 1, 2007Jun 1, 2011Oct 18, 20192 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.
End of Study (EOS) and Follow Up
Secondary Endpoints
Efficacy of ABI-009 in this patient population
End of Study (EOS) and Follow Up
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ABI-009EXPERIMENTAL -
Interventions
NameTypeDescription
ABI-009DRUGnab-rapamycin
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: Each subject must meet the following criteria to be enrolled in this study. 1. Male and female patients with histologically or cytologically confirmed diagnosis of cancer which is not amenable to curative therapy. 2. Patients with advanced non-hematologic malignancies for whom ...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence